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ABStR Act
Insulin resistance is the hallmark of Type 2 Diabetes and is still 
an unmet medical need. Insulin resistance lies at the crossroads 
of non-alcoholic fatty liver disease, obesity, weight loss and 
exercise resistance, heart disease, stroke, depression, and brain 
health. Insulin resistance is purely nutrition related, with a typ-
ical molecular disease food intake pattern. The insulin resistant 
state is accessible by TyG as the appropriate surrogate marker, 
which is found to lead the personalized molecular hepatic nu-
trition system for highly efficient insulin resistance remission. 
Treating insulin resistance with a molecular nutrition-centered 
approach shifts the treatment paradigm of Type 2 Diabetes 
from management to cure. This allows remission within five 
months, with a high efficiency rate of 85 %. With molecular 
intermittent fasting a very efficient treatment for prediabetes 
and metabolic syndrome is possible, improving the non-alco-
holic fatty liver disease (NAFL) state and enabling the body to 
lose weight in a sustainable manner.
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Introduction
Today, treatment of Type 2 Diabetes is glucose-centered and symp-
tom-oriented. The history of most patients with Type 2 Diabetes is 
a gradual rise in blood glucose concentrations over time, despite 
medication, as reported by Madsen et al. [1]. Insulin resistance is 
the hallmark of Type 2 Diabetes, but is still an unmet medical need 
even though advances in diabetes medicines have been made over 
the last several years. Ferrannini et al. [2] reported that the same is 
true for the fast and simple detection of insulin resistance. Insulin 
resistance lies at the key crossroads of metabolic and mitochondri-
al dysfunction, visceral fat, non-alcoholic fatty liver (NAFL), muscle 
exercise and weight loss resistance, subclinical inflammation, met-
abolic syndrome (MetS), overweight, and obesity, and is charac-
terized by epigenetically driven accelerated aging, as Nannini et al. 
[3] reported. Insulin resistance plays a key role in a reduced capa-
bility of the immune system to kill pathogens such as viruses and 
bacteria, as De Rosa et al. [4] and Chávez-Reyes et al. [5] reported. 
Vestergaard Jensen et al. [6] reported insulin resistance as an im-
portant risk factor for community-acquired pneumonia. Insulin re-
sistance predisposes to cardiovascular disease and shortens human 
lifespan, as data from Gardner et al. [7] showed. Insulin resistance 
is reported to drive other major non-communicable diseases, such 
as high blood pressure, chronic kidney disease (Chen et al. [8]), de-
pression (Won Lee et al. [9]; Geraets et al. [10], Ford et al. [12]), and 
stroke (Rundek et al. [11]). Alzheimer’s disease and dementia are 
also highly correlated to increased levels of triglycerides at midlife 
as data from Nägga et al. [13] showed. Insulin resistance also un-
derlies many obesity-related cancer developments, as reported by 
Sung et al. [14].
Insulin resistance is independently correlated with increased risk 
of incident diabetes in Chinese adults, as reported by Li et al. [15], 
and is closely related with higher mortality for COVID-19, accord-
ing to data reported by Ren et al. [16]. Diabetes is the most impor-
tant cause of mortality in COVID-19 hospitalized patients, as re-
ported by Corona et al. [17]. A large-scale analysis reported by 
McGovern et al. [18] found that the COVID-19 mortality risk in-
creases in patients with Type 2 Diabetes due to drastic biological 
age acceleration. The prevalence of Type 2 Diabetes in Switzerland 
is estimated to be between 5.7 and 7.0 %. Two-thirds of patients 
with Type 2 Diabetes are aware of their status, and over three-quar-
ters of those who are aware are treated, according to data from Kai-
ser et al. [19]. In the US, adults with optimal metabolic health are 
a small percentage of the population: 17.6 %, according to Araujo 
et al. [20].
Type 2 Diabetes is observed to correlate with obesity regardless 
of the genetic risks. The currently available obesity-oriented treat-
ment options for Type 2 Diabetes are either a bariatric operation, 
or a caloric weight-loss strategy that involves a very low-calorie 
diet, as reported by Kerr et al. [21], Willi et al. [22], and Xin et al. 
[23]. As observed by Baskota et al. [24], a bariatric operation can 
only be proposed for those with a BMI > 30 and should not be pro-
poses for non-diabetic obese patients.
BMI is not the main driver for insulin resistance; 
insulin resistance drives BMI
Diabetes primarily depends on visceral fat and not BMI, according 
to data from Vistisen et al. [25]. Her group found that the great ma-
jority of patients who had modest weight gains before diagnosis 
had the highest diabetes risk. Wu et al. [26] reported that, in Mex-
ican Americans, metabolic health has a greater impact on diabetes 
than overweight/obesity. Eckel et al. [27] reported that the quality 
of metabolic health was decisive for diabetes progression, irrespec-
tive of BMI. Acquired obesity independent of genetic risk is primar-
ily related to deleterious alterations in the lipid metabolism, per 
data found by Pitiläinen et al. [28] in studies of twins. Insulin resist-
ance discriminates between healthy and unhealthy phenotypes of 
obesity and leanness, as reported by Owei et al. [29] and Mon-
graw-Chaffin et al. [30] and drives the unhealthy obese phenotype 
into developing Type 2 Diabetes.
Insulin resistance has its root not only in disturbed glucose me-
tabolism but also in a derailed fatty acid metabolism leading to glu-
colipotoxic conditions and beta-cell death, as reported by Bagnati 
et al. [31]. Increased blood triglycerides accompanied by lower HDL 
values represent an insulin resistant metabolic status and are pure-
ly nutrition-related. Triglyceride levels showed a significant nega-
tive correlation with BMI and body fat. HDL cholesterol was signif-
icantly negatively correlated with waist circumference and posi-
tively correlated with body fat, as data from Telles et al. [32] 
showed.
Lipid indices, which can be easily calculated with routine labo-
ratory tests, may be useful markers for insulin resistance risk as-
sessments in clinical settings, according to Lee et al. [33]. The tri-
glyceride to HDL ratio allow identification of the insulin-resistant 
metabolic state, and a high TG:HDL-C ratio at baseline may be a 
useful surrogate indicator of future Type 2 Diabetes, as reported 
by Lim et al. [34]. The TyG index, calculated based on fasting tri-
glyceride and glucose blood values, correlates highly with insulin 
resistance. Both markers, the TG:HDL-C and TyG present a signifi-
cant association with lifetime cardiovascular risks in adults report-
ed by Rojas-Humpire et al. [35] and Si et al. [36]. The TyG index cor-
related highly with the epigenetic age acceleration, as data from 
Arpon et al. [37] showed. HOMA-IR had a significant positive cor-
relation with the TyG and TG:HDL indices, as reported by Çin et al. 
[38] and Kron et al. [39].
Triglycerides are endogenously formed after an excess of glu-
cose ingestion via a de novo lipogenesis pathway forming malon-
yl-CoA, diacylglycerols, and palmitic acid (16:0), and directly influ-
ence insulin resistance, as Lyu et al. [40] reported. Lee [41] report-
ed palmitic acid 16:0 was positively associated with incident heart 
failure in older adults. Malonyl-CoA is a master regulator for insulin 
sensitivity. Hyperglycemia with hyperinsulinemia increases malo-
nyl-CoA production and inhibits functional CPT1 activity, while and 
shunting long-chain fatty acids away from oxidation and towards 
storage in human muscle, as reported by Rasmussen et al. [42]. 
Malonyl-CoA is the first reaction step for the de novo lipogenesis 
of palmitic acid, which is positively associated with Type 2 Diabe-
tes, as data from Imamura et al. [43] showed. But de novo lipogen-
esis is also positively associated with saturated fatty acid intake and 
is elevated in patients with non-alcoholic fatty liver and Type 2 Di-
abetes, as reported by Imamura et al. [43]. The TyG index is signif-
icantly associated with incident NAFL, as reported by Kitae et al. 
[44] and Jimenez-Rivera et al. [45]. Kolb et al. [46] reported detri-
mental consequences of prolonged high insulin concentrations and 
argues for a lifestyle that limits circadian insulin levels. Skipping 
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breakfast a few times a week was associated with general adiposi-
ty and with general and central adiposity, as reported by Wado-
lowska et al. [47], and was also associated with a higher risk of in-
sulin resistance, as data from Joo et al. [48] showed. Consuming a 
three-meal diet with a carbohydrate-rich breakfast allows insulin 
dose reduction, leading to weight loss and better glycemic control 
compared with an isocaloric six-meal diet, as reported by Jakubow-
icz et al. [49].
Food choices for a molecular dietary pattern 
developing an insulin-resistant metabolic state
Compared to normal glycemic adults, adults with Type 2 Diabetes 
make different food choices, favoring a high saturated fat diet with 
higher total fat and protein and less fiber, as reported by Breen 
et al. [50]. Increased insulin resistance favors continued unhealthy 
food choices via aberrant central insulin action, as reported by 
Tiedemann et al. [51], leading to a vicious cycle in which insulin re-
sistance drives changes in taste perception, as observed by Pug-
naloni et al. [52], leading to continued eating and snacking behav-
ior. Saturated fat increases intramuscular triglycerides, and a de-
creased intake of saturated fatty acids could be beneficial in 
reducing intramuscular triglycerides and the associated risk of di-
abetes, according to data from Luukkonen et al. [53]. In obese sub-
jects with normal glycemia, elevated circulating levels of free fatty 
acids during fasting is the major metabolic derangement candidate 
driving fasting hyperinsulinemia as a homeostatic response, as re-
ported by Fryk et al. [54].
Maintaining glycemic control via a healthy fatty acid metabo-
lism may be an emerging key factor for maintaining a healthy be-
ta-cell formation for a normal glucagon metabolism, as reported 
by Grubelnik et al. [55]. Lower fiber intake of all types is associated 
with higher insulin levels. Triglyceride concentrations are poten-
tially sensitive to fiber consumption, as reported by Hannon et al. 
[56]. Fiber intake at recommended levels may be associated with 
significant cardiometabolic benefits, as data from Dong et al. [57] 
showed. Higher intakes of dietary choline and betaine are associ-
ated with lower insulin resistance in the general population, as re-
ported by Gao et al. [58].
The amount of dietary intake of animal protein was positively 
related to HOMA-IR, while plant protein was not significantly relat-
ed to insulin resistance, as reported by Azemati et al. [59]. Plant-
based proteins with polyphenols are reported by Meir et al. [60] 
and Castro-Barquero et al. [61] to improve HDL cholesterol and to 
have an inverse relationship with triglycerides. McKaye et al. [62] 
reported that a low intake of vitamin D, folate, magnesium, and 
potassium have a negative relationship to BMI, while other micro-
nutrients, such as vitamins B12 and E, do not.
A personalized molecular feeding and control 
strategy for the remission of insulin resistance
The molecular dietary pattern of humans is directly related to tran-
scriptions generating epigenetically the enzymatic pattern need-
ed for a healthy metabolism for maintaining energy homeostasis. 
An unhealthy dietary pattern leads via the epigenetically driven 
transcription to an unfavorable enzymatic pattern, leading to in-
sulin resistance to rescue the energy homeostasis, as reported by 
Hall et al. [63].
The CPT1 gene expression is epigenetically silenced in the un-
healthy obese phenotype, as data from Maples et al. [64] show. The 
β-oxidation genes are also downregulated during weight loss, pre-
serving metabolic inflexibility. Metabolic flexibility is lacking at the 
extreme of the metabolic phenotype in obese youth with dysgly-
cemia related to a defect in insulin sensitivity, limiting substrate 
utilization, as reported by Bacha et al. [65]. An epigenomic study 
by Irvin et al. [66] and Mamtani et al. [67] found that the CPT1 locus 
influenced by methylation is strongly and robustly associated with 
low-density lipoprotein cholesterol, triglycerides, as well as viscer-
al fat and waist circumference. Lai et al. [68] found that the propor-
tion of total energy supplied by carbohydrates and fat can have a 
causal effect on the risk of metabolic diseases, via the epigenetic 
status of the CPT1A gene directly influencing metabolic health 
through CPT1A gene activation or silencing. Epigenetic signatures 
are associated with dyslipidemia and are strongly associated with 
HOMA-IR, as a direct measure for insulin resistance. HOMA-IR val-
ues ≤ 3 as the threshold for Type 2 Diabetes showed a different 
methylation pattern than for individuals with HOMA-IR > 3, as re-
ported by Arpon et al. [69].
Below we present a precisely designed and personalized molec-
ular feeding strategy, integrating food research findings, and com-
bining an epigenetic view aimed at the TyG and TG:HDL indices, for 
simple metabolic steering and control, for efficient insulin resist-
ance normalization.
Compliance with ethical standards
Ethical approval: All patients were treated following an ethical ap-
proach to select the optimal treatment procedure according to 
their medical needs and the patients agreed before therapy began 
to possible reduction of their medications, when necessary.
Informed consent: Patient data and information have been com-
pletely anonymized.
Materials and Methods
A personalized nutritional method for insulin 
resistance and diabetes remission
Hepatic intermittent fasting therapy consists of two parts, always 
with a three meal per day diet. The first part is a very low calorie 
diet (VLCD) to reverse Type 2 Diabetes. The VLCD is followed by a 
personalized, hepatic-focused whole food diet, epigenetically ori-
ented to stabilizing the metabolism that was reprogrammed in the 
VLCD part. Both parts, VLCD followed by the whole food diet, are 
used for diabetes remission therapy. The VLCD combines protein 
shakes (Protiline) with selected vegetable intake focused mainly 
on sulforaphane, betaine, and choline. The personalized, hepat-
ic-focused whole food diet is applied for the normalization of MetS 
and prediabetes. The whole food diet steers and controls the per-
sonalized food intake, and is digitally supported on a molecular 
level for the individual threshold values of selected nutrients, cal-
culated not just for the key influencing macro nutrition molecules 
of saturated fats, glucose, fiber, and proteins, but also for selected 
micronutrients, geared to achieve optimal TyG and TG:HDL values, 
according to Rohner [70].
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The key molecules related to insulin resistance of the food are 
digitally calculated for molecular control. The healthy range of mo-
lecular concentration of the key food ingredients is estimated and 
visualized for the client for easy self-control, using the “EPIKonzept 
App.” The client can simply follow daily his food selection and is in-
formed about how well he is achieving on a molecular level the tar-
geted biomarkers. Possible deviations are monitored and a buddy 
support system is put in place, for increasing the self-efficacy for 
continuous optimization.
Supporting product formulas combined with therapy
Both parts of the therapy, VLCD and a personalized whole food diet, 
are supported with tailored biochemically active product formu-
las, namely EPIGENOSAN and METHYLOSAN.
Epigenosan is a tableted formula product consisting of mate tea 
extract, oil of the microalgae schizochytrium, green tea extract, an 
isoflavone from soja extract, l-arginine, magnesium, niacin, pan-
tothenic acid, folic acid, biotin, and vitamins D, E, B6, and B12.
The supplement's key ingredients are combined with l-carnitine 
l-tartrate, assuring a cofactor for the CPT1 enzyme complex, and 
is intermittently fed under fasting conditions. l-Carnitine supports 
energy metabolism and counteracts metabolic inflexibility, syn-
chronizing the intermittent fasting method and supporting the 
functionality of the β-oxidation to accelerate the clearance of tri-
glycerides. The product formula epigenosan is embedded into the 
diet, according to Rohner [71].
Epimethylosan is a capsuled formula product based on brocco-
li sprouts and white asparagus and includes choline, magnesium, 
l-methionine, coenzyme Q10, zinc, vitamins B2, B6 and B12, man-
ganese, chrome, and folic acid mediating the one-carbon metab-
olism and avoiding undernutrition of key molecules for optimal 
redox reactions. Epimethylosan is always used together with 
epigenosan.
Analytics applied and calculation of medical indices
Commonly used analytical methods were applied to determine the 
measured parameters in the figures in the result section. The TyG 
index was estimated according to the formula Ln [fasting triglycer-
ides(mg/dl) × fasting glucose (mg/dl)/2], as published by Simen-
tal-Mendia et al. [72]. The TG:HDL ratio was obtained by dividing 
the triglyceride level (mg/dl) by the HDL-C level (mg/dl) according 
to Masson et al. [73].
For the nutritional analysis, the DGExpert program was used.
The liver index was calculated according to the formula liver 
index:
(e0.953 * loge (triglycerides) + 0.139 * BMI + 0.718 * loge (ggt) + 0.053 * waist 
circumference–15.745)/(1 + e0.953 * loge (triglycerides) + 0.139 * BMI + 0.718 * loge 
(ggt) + 0.053 * waist circumference–15.745) × 100  
according to Bedogni et al. [74].
Diabetes remission group
The Type 2 Diabetes group consisted of 13 patients (▶table 1). The 
inclusion criteria for the diabetes remission group were to be not 
older than 70 years old; diagnosed with Type 2 Diabetes for not 
longer than 7 years; no heart attack history; no depressive disor-
ders at the time of application; no insulin treatment; and BMI ≥ 25. 
Diabetes remission was defined as glycated haemoglobin (HbA1c) 
of less than 47.5 mmol/mol ( < 6.5 %) and fasting glucose of less 
than 7.0 mmol/l after at least 2 month off all antidiabetic medica-
tions.
MetS/prediabetic therapy group
The MetS group consisted of 21 patients (▶table 2). The inclusion 
criteria for the MetS/prediabetic group were no depressive disor-
ders at the time of application; and BMI ≥ 20 kg/m2.
▶table 1 Diabetes remission group participants overview.




Sex Age Antidiabetic 
medication
Years diagnosed
Diab 1 33.3 29.2 29.2 F 55 Metfin 5
Diab 2 34.3 31.2 25.9 F 62 Metformin 1
Diab 3 26.8 22.2 21.3 M 54 Glavumet 2
Diab 4 32.8 27.3 26.1 M 55 None  < 1
Diab 5 31.4 26.5 24.6 F 56 Metfin 7
Diab 6 31.5 27.1 25.2 M 47 Metfin 3
Diab 7 35.9 29.4 26.7 M 46 Metfin 4
Diab 8 26.8 24.5 22.6 F 47 None  < 1
Diab 9 26.8 24.4 22.0 M 64 Metfin Unknown
Diab 10 33.3 26.5 26.7 M 61 None Unknown
Diab 11 54.3 47.6 46.5 M 50 Janumet 2
Diab 12 38.9 36.0 29.7 F 68 Januvia 2
Diab 13 41.8 36.2 31.1 F 35 None  < 1
Mean BMI 34.4 29.9 27.5
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Statistics
A two-sample t-test for dependent samples (pairwise comparison 
test) was applied using Excel. Statistical significance was consid-
ered at p  < 0.05.
Results
Typical dietary pattern of MetS, prediabetes and 
Type 2 Diabetes patients observed
The macromolecular dietary pattern of patients with MetS, predi-
abetes, or Type 2 Diabetes of both patient groups who had an ini-
tial TyG value higher than baseline shows a similar initial patholog-
ical nutritional pattern irrespective of BMI. An average intake of 
saturated fats of 35 % and unsaturated fats of 46 %; an average glu-
cose intake of 82 g/d, and an average fiber intake of 20 g/d was ob-
served.
Type 2 Diabetes remission results
The hepatic intermittent fasting therapy delivered efficient results, 
reversing Type 2 Diabetes within 60 days for all participants as 
measured by fasting glucose (▶Fig. 1). Antidiabetic medications 
could be omitted for all patients at the latest at day 60 of the VLCD 
part of the therapy. The reprogrammed metabolism in these 60 
days was stabilized during the personalized whole food nutrition 
part of the therapy up to 150 days, as shown in ▶Fig. 1. All patients 
could avoid their antidiabetic medications during the 90 days of 
the personalized whole food phase, and the diabetes remission rate 
was estimated to be 85 %, according to HbA1c and fasting glucose 
levels.
Adjuvant Type 2 Diabetes therapy results for 
uncontrolled diabetes
▶table 4 shows results achieved in a patient with uncontrolled di-
abetes.
MetS, NAFL, and prediabetes therapy results
In the MetS group, 21 patients were insulin resistant according to 
the TyG index value, and six were prediabetic. The duration of the 
therapy needed to reprogram the metabolisms of all patients in 
the MetS group and get them stably out of the diseased path was 
up to 150 days (▶Fig. 2). The method shows fast results within 30 
to 50 days.
Discussion and Conclusions
The paradox of satiety and nutrient hunger 
irrespective of BMI
A similar macro- and micromolecular dietary pattern observed for 
MetS, prediabetes, or Type 2 Diabetes patients with too high intake 
▶table 2 MetS/prediabetic group participant overview.
Patient Age Sex Medication BMI initially BMI after therapy 
(150 d)
Initial metabolic status
MetS 1 47 w None 33.2 29.3 Severe risk for insulin resistance
MetS 2 60 m None 37.2 32.5 Severe risk for insulin resistance
MetS 3 49 w Antiepileptics 31.9 30.7 Severe risk for insulin resistance
MetS 4 70 w None 31.4 26.1 Insulin resistant
MetS 5 71 m None 26.5 22.9 Insulin resistant
MetS 6 84 w None 27.8 26.2 Prediabetic
MetS 7 82 w Statin 39.6 36.1 Prediabetic
MetS 8 51 w None 23.0 20.7 Insulin resistant
MetS 9 53 m None 33.6 29.1 Prediabetic
MetS 10 32 w None 24.6 21.3 Insulin resistant
MetS 11 66 m None 32.1 29.1 Insulin resistant
MetS 12 63 m Statin 30.4 27.0 Prediabetic
MetS 13 69 m Statin 37.5 33.6 Severe risk for insulin resistance
MetS 14 76 m None 22.9 22.2 Prediabetic
MetS 15 79 w None 26.9 25.5 Insulin resistant
MetS 16 60 w None 32.7 28.8 Insulin resistant
MetS 17 56 m Antidepressive 32.8 28.1 Prediabetic
MetS 18 57 m None 31.4 25.4 Insulin resistant
MetS 19 49 m None 26.9 23.8 Insulin resistant
MetS 20 70 m None 38.8 34.2 Insulin resistant
MetS 21 43 w Statin 36.9 32.0 Insulin resistant
Mean BMI 31.3 27.8
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of saturated fats, unsaturated fats and glucose intake and a too low 
intake of fiber is in close agreement as reported by Breen et al. [50]. 
At the outset, all participants also deviated from the RDA of micro-
nutrients magnesium, potassium, and vitamin D, as also reported 
by McKaye [63]. This may point to a new paradox for insulin-resist-
ant risks, showing an abundance of glucose and palmitic acid in-
take, a shortage in unsaturated fat intake, and a scarcity for micro-
nutrients, irrespective of BMI. No strong correlation with a typical 
macromolecular nor micromolecular dietary pattern could be ex-
tracted concerning the severity of the insulin resistance, nor BMI 
nor waist circumference. But a molecular nutrition deviation irre-
spective of BMI leading to insulin resistance is particular congruent 
with nutritional stress for hypertriglyceridemia, hyperinsulinemia 
and low HDL-cholesterol. As a consequence a combination of TyG 
and TG:HDL as lead biomarkers for leading the food intake to struc-
ture the personalized program for optimal diabetes remission was 
chosen.
Type 2 Diabetes remission is not driven by calories 
only
TyG as the lead surrogate biomarker for nutritional feeding allows 
structuring personalized whole food nutrition for diabetes remis-
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▶Fig. 1 Median results of the diabetic remission group (n = 13) at three points in time: start (t = 0), after 60 days of VLCD, and after 150 days with 
the personalized whole food application. The single lead parameters and the corresponding surrogate biomarkers TyG and TG:HDL, as the leading 
medical indices for nutritional health, are shown. All data with p < 0.001, confidence interval 95 %. a Triglycerides, threshold value 1.7 mmol/l;  
b fasting glucose, threshold value 5.6 mmol/l for normal value, threshold value for diabetes remission < 7.0 mmol/l; c TyG, calculated from a and b, 
threshold value 8.73; d HbA1c, threshold value for diabetes < 47.54 mmol/mol; e HOMA Index, threshold value for Type 2 Diabetes > 3; f HDL values, 
threshold value > 1.0 mmol/l; g TG:HDL ratio, threshold value for insulin resistance > 3.0; h LDL, threshold value 3.3 mmol/l. HbA1c and fasting glucose 
are the relevant Type 2 Diabetes remission parameters, as defined.
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sion for all BMI categories ( ≥ 25), and a nutritional structure that is 
not just focused on calories (as is the main approach in today’s mar-
ketplace). Caloric aspects are taken into account of the personali-
zation algorithm of the diet, but calories are not the leading factor 
only and are calculated according to the body’s energy needs. For 
Patient 8 (▶table 1) this is shown in detail (▶table 3). Patient 8 
presented a starting BMI of 26.8. The patient’s diet before thera-
py, with a high intake of saturated fats and glucose, and low fiber 
intake with a typical in-between snacking behavior, showed simi-
lar calorie intake (isocaloric) and macronutrient distribution to her 
diet after the therapy (▶table 3).
As can be seen, the molecular distribution of the fatty acid frac-
tion was completely changed after therapy. After therapy, saturat-
ed fat intake values were normal ( < 13 g); intake of fiber was above 
the recommended value of 40 g/d; and vitamin D, magnesium, and 
potassium all reached values above the RDA. The HOMA index con-
tinued to improve after the end of the therapy (after 150 days) and 
was estimated to be 1.57 after 323 days.
Personalized molecular nutrition for Type 2 Diabetes 
remission
A highly efficient and effective insulin resistance remission result 
was achieved for all patients across all BMI categories, according to 
the lead biomarker: 85 % of the patients (11 out of 13) achieved re-
mission, and only one patient did not reach the lower threshold 
value of the TG:HDL ratio of 3.0. The TG:HDL ratio combined with 
TyG are the leading biomarkers but are weighted more to stabiliz-
ing the metabolism reprogramming that occurs during the VLCD 
part of the therapy. Our finding confirmed Achilike et al. [75], who 
found that TG:HDL has the power to produce a metabolically 
healthy phenotype. The personalized nutritional strategy reduces 
the triglyceride levels, and the molecular personalized whole food 
diet reduces the buildup of new triglycerides, leading to a negative 
balance that reaches normal levels over time. It is of utmost impor-
tance to keep the triglyceride buildup under control since triglyc-
erides can cross the blood-brain barrier and contribute to de-
creased satiety, as reported by Banks et al. [76].
Improvements in triglycerides were very fast during VLCD, av-
eraging 48 %. The fasting glucose adaptation during VLCD was also 
very fast, and all patients reached the threshold value < 7 mmol/l 
within the first 14 days.
Ten patients reached fasting glucose values < 5.6 mmol/l, and 
all patients were better than 6.3 mmol/l after completing the ther-
apy (150 days). On average, fasting glucose values improved by 
33 % (2.66 mmol/l).
Diabetes remission was always accompanied by weight loss as 
a symptomatic effect of the metabolic improvements. Kelly et al. 
[77] reported a mean diabetes remission rate of 49.4 % applying 
very low calorie diets. The VLCD part of the intermittent hepatic 
therapy, which is focused on the cause of insulin resistance, deliv-
ers more effective results, as our reported data show (▶Fig. 1).
The weight loss reached was not homogenous, since the initial 
BMI was not, and the therapy approach is not focused on calories 
only. The statistical significance and regression coefficient for dia-
betes reversion against the HOMA Index was highest for the TyG 
Index (0.61, p < 0.001), compared to the TG:HDL Index (0.41, 
p < 0.05). The weight loss achieved also showed a lower regression 
correlation to the HOMA Index (0.43, p < 0.05). This implies that 
the TyG index is the key biomarker for diabetes remission, with a 
strong focus on triglyceride normalization as a key success factor. 
This does reflect the current research that triglycerides are driving 
hyperinsulinemic conditions that disturb the glucose metabolism, 
leading to weight increase as a homeostatic defending mechanism.
The HOMA Index as a medically accepted analytical value for in-
sulin resistance was always surpassed, and on average was reduced 
by 79 %, or 6.7 units over the entire therapy length. For one hyper-
insulinemia patient, an improvement in the HOMA Index of 12 
times was observed. All patients reached the < 3 threshold point of 
▶table 3 BMI is not the driver for Type 2 Diabetes remission. Isoca-
loric nutrition of a patient before and at the end of therapy, no medi-
cation, < 1-year diagnosis, female, 47 years, initial BMI 26.8.
Isocaloric nutrition, 
composition
Before therapy After therapy
Total calories kcal/day 1676 1560
Carbohydrate g/d 188 160
Carbohydrate kcal/d 771 656
 % carbohydrate of total 
calorie intake
53 54
Proteins g/d 80 83
Proteins as kcal/d 330 338
 % protein of total calorie 
intake
20 22
Total fat g/d 66 63
Fat as kcal/d 611 590
 % of total fat intake 36 38
Saturated fat g/d 27.6 12.5
Monounsaturated fat g/d 21.6 28.2
Polyunsaturated fat g/d 8.6 17.6
Omega-3 fatty acids g/d 0.8 3.3
Fiber g/d 26.7 44.9
 % fiber of total calorie 
intake
6.5 11.8
Vitamin D µg/day 1.3 9.2
Magnesium mg/day 279.0 577.0
Potassium g/d 2.4 4.3
Fasting blood values/
anthropometric data
Before therapy After therapy
Triglyceride mmol/l 2.7 1.4
HDL mmol/l 1.2 1.3
LDL mmol/l 3.9 3.1
Glucose mmol/l 9.1 5.4




BMI kg/m2 26.8 22.6
Waist circumference cm 97.0 90.0
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the HOMA Index (3.8 reached for this patient, with a starting HOMA 
Index of 28). Over the full course of the therapy, a success rate 
of > 90 % could be estimated according to the HOMA Index. All pa-
tients of the diabetes group reached HbA1c values < 47.54 mmol/
mol, at the end of the 150 days time window. The average improve-
ment in HbA1c was 17 %, or 21.8 mmol/ml, which is higher than the 
6.65 mmol/mol achieved in the caloric diabetes remission study 
reported by Ades et al. [78] that had a VLCD with a similar therapy 
duration of six months.
The importance of the triglyceride metabolism as presented is 
further supported by Ma et al. [79] and Lim et al. [80] who report 
that triglyceride levels are independently correlated with insulin 
resistance and islet beta-cell function in individuals with dyslipi-
demia.
We observed a relationship between the time required to 
achieve the threshold value of fasting glucose and the prior dura-
tion of Type 2 Diabetes and medication taken, but due to the lim-
ited number of patients this observation is in conclusive.
Adjuvant diabetes therapy to the uncontrolled 
medicated patient
Uncontrolled diabetes can be improved efficiently by restoring nor-
mal triglyceride levels, leading to normal insulin levels, by applying 
the personalized whole food part of the therapy (▶table 4).
The initial fasting glucose value of 12.28 mmol/l was reduced to 
5.7 mmol/l in 30 days, while keeping the antidiabetic medication 
unchanged. Insulin resistance according to the HOMA Index was 
reduced by a factor of more than 10 (from 39.2 to 3.2), almost 
reaching the lower threshold value of 3.0 within 30 days of appli-
cation. The TyG index estimated was 8.86 after application (thresh-
old 8.73) and indicates improved status or almost no remaining in-
sulin resistance. The triglycerides level was reduced from 
3.58 mmol/l to 1.55 mmol/l (but still taking statins). Cortisol was 
reduced from 56 to < 28. The vicious cycle of increased cortisol 
paired with insulin resistance leading to hyperinsulinemia driving 
visceral fat was changed from a pathologic insulin level from 0.52 
to a normal insulin level of 0.09 within 30 days of application.
Triglycerides have emerged as a new risk factor for cardiovascu-
lar disease in Type 2 Diabetes, as reported by Ye et al. [81]. Accord-
ing to Halldin et al. [82], the risk factor cholesterol has shifted more 
toward the risk factor triglycerides. Statins do not lower triglycer-
ides adequately, as reported by Toth et al. [83] and, as reported by 
Shimoda et al. [84], the durability of the glucose-lowering effects 
from DPP-4 inhibitors can be better maintained if strict triglycer-
ide management takes place.
Insulin resistance remission for MetS and 
prediabetes patients normalizing triglycerides
Normalization of MetS, prediabetes, and amelioration of NAFL is 
mediated by the reduction of triglycerides, similar to what is ob-
served in Type 2 diabetes patients. The patients reported in their 
anamnesis a weight loss resistance which can be overcome with a 
fast normalization of the dyslipidemic state and triglyceride levels 
within the two first weeks of the personalized whole food part of 
the therapy. The molecular nutrition focused on the “one carbon” 
and CPT1 metabolism of the whole food part of the intermittent 
hepatic therapy delivers fast triglyceride amelioration. After 30 days 
of application of the personalized whole food intermittent fasting 
therapy part, the average TyG index was improved by 9 %. Sixteen 
patients reached the lower threshold value < 8.73 concerning insu-
lin resistance but also TG:HDL < 3. This corresponds to > 76 % effi-
ciency for insulin resistance normalization respectively remission. 
▶table 4 Time course of a Type 2 Diabetes patient with uncontrolled diabetes (male, 55 years).
Analysis Before One month after Norm value Unit
Cholesterol 2.74 * 2.4 *  < 5.2 mmol/l
HDL cholesterol 0.77 0.79  > 1.0 mmol/l
LDL cholesterol 1.14 * 1.21 *  < 3.3 mmol/l
Triglycerides 3.58 * 1.55 *  < 1.7 mmol/l
Glucose 12.28 *  * 5.77 *  * 3.9–5.6 mmol/l
TyG 10.45 8.86  < 8.73 –
ASAT/GOT 0.62 0.63  < 0.85 μmol/s * l
ALAT/GPT 0.88 0.69  < 0.85 μmol/s * l
GGT 1.24 1.05  < 1.19 μmol/s * l
Cortisol 56  < 28 nmol/l
Insulin (ip) 0.52 0.09 0.02–0.12 nmol/l
HOMA Index 39.2 *  * 3.2 *  *  < 3 –
Waist circumference 115 109  < 94 cm
BMI 31.6 29.4 20–25 kg/m2
Bodyweight 99.8 92.9 kg
 *  Statins;  *  *  Antidiabetics.
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Those five patients who were still slightly above the threshold 
showed good improvement but needed more time to reach the 
lower threshold. All initially prediabetic patients were no longer 
prediabetic after 150 days of application. The average improve-
ment in triglyceride reduction was 33 % within 150 days. This is in 
accordance to Farell et al. [85] of key importance in breaking weight 
loss resistance, since early and established NAFL is responsible for this 
effect due to triglyceride accumulation. We measured an average im-
provement of the liver index within the first 50 days of 29 units. The 
initial median liver index was estimated as 81 units. According to Khan 
et al. [86], the modulation of triglycerides and insulin resistance rep-
resents a potential new strategy for NAFL treatment.
Triglyceride values stabilized after 50 days, HDL cholesterol in-
creased, and LDL cholesterol decreased, stabilizing the metabolic 
and weight loss goals that had been reached.
Weight reduction occurred as a result of the metabolic improve-
ment, with a mean BMI reduction of about 8 % within 50 days and 
up to 11 % within 150 days. To date, weight loss is the only existing 
therapy for NAFL according to Hydes et al. [87]. Our results suggest 
that, with a triglyceride and insulin resistance focus paired for 
weight loss, a new efficient NAFL treatment option is available.
As conclusion, the applied therapeutically method allows revers-
ing the Type 2 Diabetic metabolism within 60 days and remission 
within 150 days with high efficiency. This shifts the treatment para-
digm for Type 2 Diabetes from management to cure. Applying these 
method to patients with MetS and/or prediabetes can normalize their 
insulin resistance or prediabetes completely within 50 to 150 days. 
Our results favor a molecular nutritional diabetes prevention and re-
mission strategy that is focused on triglyceride normalization with 
TyG as the lead biomarker, but that also combines a caloric approach 
enabling dietary molecular nutrition with an epigenetic point of view 
as a completely new diabetes prevention and remission strategy, and 
also a new treatment option for NAFL patients.
The pilot study has strengths and also weaknesses. Its major 
strength is the achievement of insulin resistance and Type 2 Diabe-
tes remission in a significant, fast, and highly efficient way. The 
method is completely digitally supported for easy application and 
combines smart formulas of active ingredients to support the nu-
tritional and metabolic adaptation. The presented method can es-
tablish a new treatment option that cures Type 2 Diabetes. The 

















































t = 0 t = 30 d t = 50 d t = 150 d
TyG (–)
▶Fig. 2 Median results of the MetS/prediabetic group (n = 21) at four-time windows: start t = 0, at 30 days, at 50 days, and at 150 days. The single 
lead parameters and the corresponding surrogate biomarkers TyG and TG:HDL ratio as the leading medical index for nutritional health, are shown. All 
data with p < 0.001, confidence interval 95 % a Triglyceride course, threshold value 1.7 mmol/l; b fasting glucose course, threshold value 5.6 mmol/l 
for normal; c TyG course, calculated from a and b, threshold value 8.73; d HDL values, threshold value > 1.0 mmol/l; e TG:HDL ratio, threshold value 
for insulin resistance > 3.0; f LDL, threshold value 3.3 mmol/l.
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Additional studies might be of interest from a scientific point of 
view, both to measure further data from more homogenous pa-
tient groups, and also to explore the epigenetic effects involved. 
However, from a practical and an application point of view, the 
methodology is very robust, proven, simply to apply, completely 
digitally supported, and ready to be used on a larger scale. Apply-
ing this new paradigm of a personalized molecular dietary pattern 
control for insulin resistance remission could revolutionize diabe-
tes medicine and could also contribute beneficially to reduce the 
economic burden of Type 2 Diabetes and its related diseases.
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